Alto Neuroscience Appoints Raymond Sanchez, M.D., to Board of Directors, Strengthening Leadership as Company Advances Late-Stage Precision Psychiatry Pipeline Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company pioneering the development of novel precision medicines for neuropsychiatric disorders, today…
Innoviva Specialty Therapeutics Earns Dual Nominations for 2025 Prix Galien USA Best Pharmaceutical Product Award for ZEVTERA® and XACDURO® Innoviva Specialty Therapeutics, a wholly owned subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced that two of its flagship infectious disease therapies…
Infinity Bio Partners with Austrian Institute of Technology to Deliver Antibody Reactome Profiling Across Europe Infinity Bio, Inc., a pioneering leader in advanced immune system analysis, has announced a strategic partnership with the Austrian Institute of Technology (AIT), one of…
TriSalus Life Sciences Announces Strong Q2 2025 Results, Affirms Full-Year Outlook, and Advances Strategic Focus on Liver-Directed Therapies TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company pioneering innovative delivery solutions for treating solid tumors, today reported its financial results…
Bayer and Kumquat Biosciences Forge Global Exclusive Agreement to Advance Next-Generation KRAS G12D Inhibitor in Precision Oncology Bayer AG, a global life sciences company with a growing presence in oncology, and Kumquat Biosciences Inc., a clinical-stage biotechnology company founded by…
Laxxon Medical Achieves Major Product Development Milestone with Novel SPID®-Based Oral Modified-Release Formulation of Veru’s Enobosarm Laxxon Medical Corp., a pioneering pharmaceutical technology company specializing in next-generation oral drug delivery systems, announced a significant advancement in its collaboration with Veru…
Thermo Fisher Scientific Secures FDA Approval for NGS-Based Companion Diagnostic to Support New HER2-Targeted NSCLC Therapy Thermo Fisher Scientific Inc. (NYSE: TMO), the global leader in serving science, has announced a significant regulatory milestone with the U.S. Food and Drug…
Newron Announces Landmark Preclinical Study Supporting Evenamide’s Potential to Transform Schizophrenia Treatment Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for diseases of the central and peripheral nervous system, has highlighted…
CGT Global Strengthens Advisory Leadership with Appointment of Dr. Andrew Branagan, Enhancing Expertise in Hematologic Malignancies and Advanced Cell and Gene Therapy Development CGT Global, a biotechnology innovator dedicated to advancing the development, manufacturing, and delivery of cutting-edge cell and…
Precision BioSciences Reports Second Quarter 2025 Financial Results, Highlights Strong Clinical Progress in Gene Editing Programs, and Extends Cash Runway Into 2027 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company harnessing its proprietary ARCUS® genome editing platform to develop…
WuXi Biologics Earns Coveted Spot on CDP’s Supplier Engagement A List, Strengthening Its Position as a Global ESG Leader WuXi Biologics (2269.HK), a globally renowned Contract Research, Development, and Manufacturing Organization (CRDMO), has once again underscored its commitment to sustainability…
Promega and Aobious Reach Comprehensive Settlement in Patent Infringement Lawsuit Over Bioluminescent Technology Promega Corporation and Aobious Inc. have officially concluded a contentious legal battle over bioluminescent reagent patents, reaching a settlement agreement that addresses a lawsuit involving proprietary furimazine…
